Prognostic significance of APOE and FOXP3 immunohistochemical expression in papillary thyroid carcinoma and concomitant Hashimoto’s thyroiditis | ||
| Zagazig University Medical Journal | ||
| Article 12, Volume 31, Issue 6, June 2025, Pages 2302-2315 PDF (1.69 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/zumj.2025.321083.3602 | ||
| Authors | ||
| Heba Mahmoud Abdelgeleel1; Ebtisam R Qasem* 2; Ihab Matar3; Adel A Elnossiry4; Essam Adel Abdelrahman5; Noha F Elaidy6 | ||
| 1pathology department , faculty of medicine, Zagazig university | ||
| 2clinical oncology department , faculty of medicine ,zagazig university hospitals | ||
| 3Surgical Oncology Department, Ismailia Teaching Oncology Hospital. | ||
| 4surgical oncology depart.faculty of medicine Zagazig university | ||
| 5Internal Medicine-faculty of medicine Zagazig University | ||
| 6Pathology Department, Faculty of Medicine, Zagazig University | ||
| Abstract | ||
| Background: APOE is involved in immunological control mediated by lymphocytes. The biological processes of several malignant tumors were accelerated by its overexpression. APOE reduces antigen-activated lymphocytes, which has an impact on immunity. Regulatory T cells (Treg) are a subset of T helper (CD4+) cells, which are essential to the immune system because they counteract the actions of T cells to decrease autoimmune reactions. For this regulation, the transcription factor forkhead box (FOXP3) is crucial. Due to their involvement in the onset and progression of PTC, APOE and FOXP3 may be utilized in molecularly targeted treatments. Immunocheck-point inhibitors are essential to support novel immunotherapy approaches in treatment and increase the prognosis of PTC linked with HT since both indicators have significant immunoregulatory processes. Aim of study: Exploring the effect of APOE and FOXP3 on PTC prognosis and its clinical outcome, which could help in novel treatments development against PTC. Patients and Methods: 46 tissue blocks were obtained retrospectively spanning the period between May 2018 to May 2023. These sections are then exposed to all steps of IHC technique for staining of APOE and FOXP3 Results: Positive APOE and FOXP3 expression was significantly correlated with poor clinical parameters. Conclusion: Increased tissue expression of novel immunomarkers APOE and FOXP3 are associated with poor clinical outcome which predicted the possibility of using these markers as targeted therapy in combination with the ordinary used therapies for improving the prognosis of PTC with associated HT. | ||
| Keywords | ||
| immunotherapy; PTC; immunohistochemistry; prognosis | ||
|
Statistics Article View: 18,012 PDF Download: 57 |
||
